GlassScriptPhysician profile
Ruben D Villa
NPI 1659367647
$18,789.30
in general payments reported to CMS, 2019-2025
19 companies · $15.16 in 2025
The $15.16 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $152 · 2021: $11K · 2022: $5,905 · 2023: $381 · 2024: $1,304 · 2025: $15.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $957 · Food and Beverage: $723 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $957.47 |
| Food and Beverage | $722.80 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16,370.09 | 2021-2024 | |
| Boston Scientific Corporation | $1,178.59 | 2021-2024 | Varithena Administration Pack |
| Otsuka America Pharmaceutical, INC. | $350.40 | 2019-2024 | Jynarque |
| Nxstage Medical, INC. | $231.19 | 2022 | |
| Fresenius USA Marketing, INC. | $116.32 | 2019-2022 | |
| Vifor Pharma, INC. | $90.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.45 | 2023-2024 | Jardiance |
| Amgen INC. | $66.82 | 2019-2024 | Krystexxa |
| Bard Peripheral Vascular, INC. | $64.97 | 2020-2021 | |
| Akebia Therapeutics INC | $55.20 | 2020-2024 | Vafseo, Auryxia |
| Arbor Pharmaceuticals, INC. | $34.12 | 2020 | |
| Cormedix INC. | $30.64 | 2024 | Defencath |
| Mallinckrodt Enterprises LLC | $29.02 | 2019 | |
| Travere Therapeutics, INC. | $24.41 | 2023 | |
| Calliditas Therapeutics US INC. | $23.12 | 2023 | Tarpeyo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.71 | 2024 | Ibsrela |
| Globus Medical, INC. | $15.16 | 2025 | Senza |
| Astrazeneca Pharmaceuticals LP | $15.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.